Navigation Links
Chemotherapy effective for patients with resected SCLC or large-cell neuroendocrine carcinoma
Date:6/15/2012

DENVER Research presented in the July 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, concluded that patients with limited large cell neuroendocrine tumors or with limited stage small-cell lung cancer who were treated with perioperative chemotherapy and surgery had better overall survival outcomes than patients treated with surgery alone.

Small-cell lung cancer (SCLC) represents about 15 percent of lung cancers annually. Of those, about 30 percent of patients have limited disease SCLC. Whereas large-cell neuroendocrine carcinoma (LCNEC) is a subgroup of large-cell carcinoma, that has characteristics similar to SCLC. Surgery in these groups of patients are rare and researchers wanted to know if perioperative chemotherapy would benefit the patients.

The retrospective study looked at 74 patients who underwent lung cancer surgery at the Surgical Centre Marie Lannelongue in Le Plessis Robinson, France between 1979 and 2007. Forty-five patients underwent surgery combined with perioperative chemotherapy and 29 underwent surgery alone. They found, "treatment involving surgery plus perioperative chemotherapy was associated with a significantly longer OS (overall survival) than surgery alone (6.1 years and 2.3 years, respectively)."

The authors point out that there were limitations to their study. Because the data was from 1979, the previous staging system was used. The authors also point out that, "more patients had a node involvement in the chemotherapy group, indicating that physicians may have offered chemotherapy to patients with more advanced disease." However, no conclusion could be made because of the, "small population examined in this study, its retrospective nature, the difference in follow-up between the two groups and the heterogeneity of the combined treatments."

The authors point out that due to the rarity of this population, a prospective trial is unlikely to be feasible and these retrospective data may be of value.


'/>"/>

Contact: Kristal Griffith
Kristal.Griffith@iaslc.org
720-325-2952
International Association for the Study of Lung Cancer
Source:Eurekalert

Related medicine news :

1. Chemotherapy proves life-saving for some leukemia patients who fail induction therapy
2. Adding drug to standard chemotherapy provides no survival benefit for older lung cancer patients
3. Genetic predictor of breast cancer response to chemotherapy
4. Chemotherapys effect on overall survival seems to increase based on tumor size
5. Accelerated chemotherapy given before surgery benefits patients with muscle-invasive bladder cancer
6. Breast MRI helps predict chemotherapys effectiveness
7. Why chemotherapy fails
8. Overexpression of proteins 14-3-3 related to chemotherapy resistance
9. HIV Prevention Pill Cost-Effective for High-Risk Men: Study
10. Pig stomach mucins are effective as anti-viral agents for consumer products
11. Lower-Dose Radioiodine Effective Against Thyroid Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... 2016 , ... People across the U.S. are sharpening their pencils and honing ... contest in which patients and their families pay tribute to a genetic counselor by ... Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In ...
(Date:6/24/2016)... ... 24, 2016 , ... National recruitment firm Slone Partners is pleased ... and genomics experience, as Vice President of North American Capital Sales at HTG ... leading the sales team in the commercialization of the HTG EdgeSeq system and associated ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas ... Brasil as the company,s second affiliate in Latin America . ... ... of Astellas Farma Colombia ... ...
(Date:6/23/2016)... , June 23, 2016  Experian ... integrating and transforming the patient payment and ... several innovative new products and services that ... its revenue cycle offerings. These award-winning solutions ... efficient workflows, remain compliant in an ever-changing ...
Breaking Medicine Technology: